Public/Private Partnership Is Best Vehicle For Active Rx Surveillance System
Executive Summary
An active drug safety surveillance system is "doable," and would cost in the tens of millions of dollars, GlaxoSmithKline Chief Medical Officer Ronald Krall said during a recent Institute of Medicine symposium on the future of drug safety
You may also be interested in...
FDA’s Implementing Visionary: A Conversation With COO John Dyer
FDA's efforts to help usher in the bioinformatics era are personified by Deputy Commissioner for Operations John Dyer
Avandia Advisory Cmte. Could Be Observational Data’s Coming Out Party
The recommendations from FDA's joint advisory committee review of a signal of potential cardiovascular risk for GlaxoSmithKline's type 2 diabetes therapy Avandia (rosiglitazone) will likely be determined by how much weight the panel gives to meta-analysis as a means of assessing a drug's safety
FDA’s Implementing Visionary: A Conversation With COO John Dyer
FDA's efforts to help usher in the bioinformatics era are personified by Deputy Commissioner for Operations John Dyer